



### 3. Statistical Analysis

Data was assessed using statistical program SPSS10. student t test and chi square test were employed to evaluate and establish correlation between lipid profile and microvascular complication in DM. P value of <0.05 was considered as significant.

between 200-239 mg/dl whereas 3 patients had >239 mg/dl. (table no 1)

**Table 1: Type 1 DM patients and their lipid profile**

COMPLICATION	TC		LDL			VLDL		TG		
	<250	≥250	<100	100-129	>129	≤40	≥40	<200	200-239	>239
NEUROPATHY	14	24	7	19	12	38	0	38	0	0
NEPHROPATHY	12	21	4	11	18	33	0	33	0	0
RETINOPATHY	24	46	9	36	25	64	6	64	3	3

### 4. Results

In our study a total of 260 patients were enrolled and evaluated, among them there were 141 T<sub>1</sub>DM (53 male and 88 female) patients and 119 T<sub>2</sub>DM (41 male and 78 female) patients.

In T<sub>1</sub>DM patients, 38 patients have neuropathy, 14 patients had their TC ≤250 mg /dl while 24 patients had their TC >250mg/dl. 31 patients have HDL <40, whereas 7 patient have HDL within normal limit and none have HDL above baseline. 7 patients have LDL <100mg/dl, 19 have between 100-129mg/dl whereas 12 patient have LDL ≥129mg/dl and finally all these 38 patients have their VLDL and TG levels below 40 and 200 respectively. 33 patients who had nephropathy, 12 patients had TC ≤250 mg/dl while 21 patients had TC >250mg/dl 28 patients have HDL <40, whereas 5 patient have HDL within normal limit and none have HDL above baseline. 4 patients have LDL <100mg/dl, 11 have between 100-129mg/dl whereas 18 patient have LDL ≥129mg/dl and finally all these 33 patients have their VLDL and TG levels below 40 and 200 respectively. Among 70 retinopathy patients, 24 patients had TC ≤250mg/dl while 46 patients had TC >250 mg/dl. 57 patients have HDL <40, whereas 13 patient have HDL within normal limit and none have HDL above baseline. 9 patients have LDL <100mg/dl, 36 have between 100-129mg/dl whereas 25 patient have LDL ≥129mg/dl. 64 patients have VLDL level ≤ 40mg/dl and 6 patients have ≥40mg/dl and finally 64 patients have TG ≤200mg/dl, 3 patients have

In T<sub>2</sub>DM patients, 48 patients have neuropathy, 27 patients had their TC ≤250 mg /dl while 21 patients had their TC >250mg/dl. 32 patients have HDL <40, 14 patient have HDL within normal limit and 2 patients have HDL above baseline. 4 patients have LDL <100mg/dl, 4 have between 100-129mg/dl whereas 40 patient have LDL ≥129mg/dl. 36 patients have VLDL ≤40mg/dl, and 12 patients have >40mg/dl. TG levels were below 200mg/dl among 4 patients, 11 patient have 200-239 mg/dl and finally 33 patients have TG >239 mg/dl. Among 18 patients who had nephropathy, 4 patients had TC ≤250 mg/dl while 14 patients had TC >250mg/dl, 15 patients have HDL <40, whereas 3 patient have HDL within normal limit and none have HDL above baseline. 1 patients have LDL <100mg/dl, none between 100-129mg/dl whereas 17 patients have LDL ≥129mg/dl. 13 patients have VLDL ≤40mg/dl, and 5 patients have >40mg/dl. TG levels were below 200mg/dl among 1 patient, 6 patient have 200-239 mg/dl and finally 11 patients have TG >239 mg/dl. Among 70 retinopathy patients, 22 patients had TC ≤250mg/dl while 31 patients had TC >250 mg/dl. 30 patients have HDL <40, whereas 21 patient have HDL within normal limit and 2 patients have HDL levels above baseline. 5 patients have LDL <100mg/dl, 6 have between 100-129mg/dl whereas 42 patient have LDL ≥129mg/dl. 35 patients have VLDL level ≤ 40mg/dl and 18 patients have >40mg/dl and finally 4 patients have TG ≤200mg/dl, 32 had between 200-239mg/dl whereas 17 patients have >239mg/dl (table no 2).

**Table 2: Type 2 DM Patient and their lipid profile**

COMPLICATION	TC		LDL			VLDL		TG		
	<250	≥250	<100	100-129	>129	≤40	≥40	<200	200-239	>239
NEUROPATHY	27	21	4	4	40	36	12	4	11	33
NEPHROPATHY	4	14	1	0	17	13	5	1	6	11
RETINOPATHY	22	31	5	6	42	35	18	4	32	17

### 5. Discussion

Various studies have proven the role of elevated serum lipids with macro vascular complications of DM like coronary artery disease but, studies of association of lipids with specific micro vascular complications of DM have shown varying results. Hiraga<sup>13</sup> et al, Hernandez<sup>14</sup> et al and Ogbera<sup>15</sup> et al established in their respective studies that lipoproteins are independent risk factor for CAD in diabetic patients. There are few studies available which have dealt with serum lipid and its association with microvascular complication with diabetes.

The present study was conducted in Department of Medicine, Sardar Patel Medical College, Bikaner. 260 patient having diabetes (141 T<sub>1</sub>DM and 119 T<sub>2</sub>DM patients)

was enrolled for our study. The mean age for type 1 DM subgroup was 32.4±6.4yrs whereas for type 2 DM subgroup was 56.8±8.2 yrs. The average duration of diabetes was 10.3±5.4 yrs. The mean value of fasting and post prandial blood sugar was 182±56 and 255.9±80mg/dl respectively. Thus we see there is predilection of development of microvascular complication with the poorer control of diabetes. Duration of diabetes also seemed to play a role as nearly all the patient had either one or another form of microvascular complication. Our study results showed a positive correlation of microvascular complication with total cholesterol, LDL, VLDL, and triglyceride (p<0.001). It was observed that retinopathy was more common in male in comparison to female in type 1 DM. Neuropathy was more common in female in comparison to male in type 2 DM patients. Low level of HDL cholesterol were highly significant in both retinopathy (p<0.001) and neuropathy

( $p < 0.001$ ) while association with nephropathy was also significant ( $p < 0.01$ ). (Table no 3 and 4)

**Table 3:** Statistical analysis of lipid profiles with microvascular complication

	NEUROPATHY				NEPHROPATHY				RETINOPATHY			
	TYPE1DM		TYPE2DM		TYPE1DM		TYPE2DM		TYPE1DM		TYPE2DM	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
<b>TC</b>	194.4	26.8	232.8	39.3	203.4	24.2	256.3	32.8	191.9	22.3	244.5	54.0
<b>LDL</b>	124.3	25.2	161.6	33.5	135.4	25.9	183.2	26.9	123.3	22.1	172.0	48.1
<b>VLDL</b>	25.7	4.9	38.1	6.9	26.2	4.7	39.4	5.9	27.9	7.5	38.8	6.7
<b>TG</b>	133.1	26.6	190.3	34.7	135.9	25.4	196.3	29.6	141.9	37.7	193.8	33.3
<b>HDL</b>	43.8	6.7	39.1	7.9	43.7	5.5	34.7	4.9	42.7	6.7	39.2	2.6

**Table 4:** Statistical analysis of lipid profiles with microvascular complication

	NEUROPATHY		NEPHROPATHY		RETINOPATHY	
	t	P	t	P	t	P
<b>TC</b>	5.090	<0.001	6.565	<0.001	7.359	<0.001
<b>LDL</b>	5.678	<0.001	6.225	<0.001	7.512	<0.001
<b>VLDL</b>	9.291	<0.001	8.770	<0.001	8.391	<0.001
<b>TG</b>	8.337	<0.001	7.644	<0.001	7.954	<0.001
<b>HDL</b>	3.124	0.002	5.823	<0.001	2.603	0.010

**Table 5:** Variation of HDL with type 1DM and type 2 DM

COMPLICATION	TYPE 1 DM			TYPE 2 DM		
	<40	40-60	>60	<40	40-60	>60
<b>NEUROPATHY</b>	27	21	4	36	12	4
<b>NEPHROPATHY</b>	4	14	1	13	5	1
<b>RETINOPATHY</b>	22	31	5	35	18	4

## 6. Conclusion

Lipid abnormalities were associated with an increased risk of all three diabetic complications studied, i.e. diabetic nephropathy, retinopathy, and incident CAD events. This study demonstrates correlation among HDL-C, TG and non-HDL-C with risk for microvascular events following the diagnosis of DM. Numerous studies have shown decreased risk in macro vascular disease in patients with diabetes who are treated with lipid-lowering agents, especially statins. As these microvascular complications were more with poorer glycaemia control and deranged lipid profile hence patient of DM should be regularly monitored for fasting/PP sugar, lipid profile and should be subjected to regular screening for microvascular complication.

## References

- [1] Joshi SR, Parikh RM. India - diabetes capital of the world: now heading towards hypertension. *J Assoc Physicians India*. 2007;55:323-4. [PubMed].
- [2] Kumar A, Goel MK, Jain RB, Khanna P, Chaudhary V. India towards diabetes control: Key issues. *Australas Med J*. 2013;6(10):524-31. [PMC free article] [PubMed]
- [3] Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes-estimates for the year 2000 and projections for 2030. *Diabetes Care*. 2004;27(3):1047-53. [PubMed]
- [4] Whiting Dr, Guariguata L, Weil C, Shawj. IDF Diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. *Diabetes Res ClinPract*. 2011;94:311-21. [PubMed]
- [5] "Update 2014". IDF. International Diabetes Federation. Retrieved 29 November 2014.
- [6] Williams textbook of endocrinology (12th ed.). Philadelphia: Elsevier/Saunders. pp. 1371-1435. ISBN 978-1-4377-0324-5.
- [7] Shi, Yuankai; Hu, Frank B. "The global implications of diabetes and cancer". *The Lancet* 383 (9933): 1947-8. doi:10.1016/S0140-6736(14)60886-2. PMID 24910221.
- [8] ^ Jump up to:<sup>a b c</sup> Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, et al. (Dec 15, 2012). "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010". *Lancet* 380 (9859): 2163-96. doi:10.1016/S0140-6736(12)61729-2. PMID 23245607.
- [9] "The top 10 causes of death Fact sheet N°310". World Health Organization. Oct 2013.
- [10] "Diabetes Fact sheet N°312". WHO. October 2013. Retrieved 25 March 2014
- [11] De Pablos, Martinez J. prevalence of micro and macro albuminuria in a canarian population of T<sub>2</sub>DM patients. *diabetes metab*. 1998;24(4):337-43.
- [12] National Cholesterol Education Program: *Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)*. NIH Publication No. 02-5215. MD: National Heart Lung and Blood Institute, Bethesda; 2002.
- [13] Hiraga T, Kobayashi Y, Okubo M, Nakanishi K. Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patient with diabetes. *Diabetes care* 1995;18:241-4
- [14] Hernandez C, Francisco G, Chacon P, Simo R. Lipoprotein (a) as a risk factor for

cardiovascular mortality in type 2 diabetes patients: a 10 year follow up study. Diabetes Care 2005 ;28(4):931-3.  
[15] OgberaAO, AzenaborAO. Lipoprotein (a), c reactive protein and some metabolic cardiovascular factor in type 2 DM .Diabetes metabolic syndrome, 2010;2:51.

